A multicentric outbreak of Candida auris in Mexico: 2020 to 2023.

IF 3.8 3区 医学 Q2 INFECTIOUS DISEASES
Patricia Rodríguez-de la Garza, Carlos de la Cruz-de la Cruz, José Iván Castillo Bejarano, Alicia Estela López Romo, Jorge Vera Delgado, Beatriz Aguilar Ramos, Mirna Natalia Martínez Neira, Daniel Siller Rodríguez, Héctor Mauricio Sánchez Rodríguez, Omar Alejandro Rangel Selvera
{"title":"A multicentric outbreak of Candida auris in Mexico: 2020 to 2023.","authors":"Patricia Rodríguez-de la Garza, Carlos de la Cruz-de la Cruz, José Iván Castillo Bejarano, Alicia Estela López Romo, Jorge Vera Delgado, Beatriz Aguilar Ramos, Mirna Natalia Martínez Neira, Daniel Siller Rodríguez, Héctor Mauricio Sánchez Rodríguez, Omar Alejandro Rangel Selvera","doi":"10.1016/j.ajic.2024.07.012","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Candida auris, an emerging multidrug-resistant yeast, has become a global concern due to its association with nosocomial outbreaks and resistance to antifungal medications. The COVID-19 pandemic has exacerbated the situation, with several outbreaks reported worldwide, including in Mexico. We describe the clinical and microbiological characteristics of a multicentric outbreak in private institutions in Mexico.</p><p><strong>Methods: </strong>A retrospective observational study was conducted across 4 Christus Muguerza Hospital Health Care System facilities in Monterrey, Mexico, where simultaneous outbreaks of C auris occurred. Patients with colonization or infection with C auris between September 2020 and December 2023 were included.</p><p><strong>Results: </strong>Analysis revealed 37 cases, predominantly male (median age, 55.8years). While most cases were initially colonization, a significant proportion progressed to infection (32.4%). Patients with documented infection had longer intensive care unit and hospital stays, often requiring mechanical ventilation. Antifungal treatment varied, with empirical fluconazole being the first drug in most cases, followed by anidulafungin and caspofungin. Resistance to fluconazole was widespread, but susceptibility to other antifungals varied. The overall mortality rates were high (40.5%), with no significant difference in median survival between colonized and infected patients.</p><p><strong>Conclusions: </strong>We reported a high rate of infection in previously colonized cases associated with longer hospital lenght stay, and a high susceptibility to echinocandins.</p>","PeriodicalId":7621,"journal":{"name":"American journal of infection control","volume":null,"pages":null},"PeriodicalIF":3.8000,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of infection control","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ajic.2024.07.012","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Candida auris, an emerging multidrug-resistant yeast, has become a global concern due to its association with nosocomial outbreaks and resistance to antifungal medications. The COVID-19 pandemic has exacerbated the situation, with several outbreaks reported worldwide, including in Mexico. We describe the clinical and microbiological characteristics of a multicentric outbreak in private institutions in Mexico.

Methods: A retrospective observational study was conducted across 4 Christus Muguerza Hospital Health Care System facilities in Monterrey, Mexico, where simultaneous outbreaks of C auris occurred. Patients with colonization or infection with C auris between September 2020 and December 2023 were included.

Results: Analysis revealed 37 cases, predominantly male (median age, 55.8years). While most cases were initially colonization, a significant proportion progressed to infection (32.4%). Patients with documented infection had longer intensive care unit and hospital stays, often requiring mechanical ventilation. Antifungal treatment varied, with empirical fluconazole being the first drug in most cases, followed by anidulafungin and caspofungin. Resistance to fluconazole was widespread, but susceptibility to other antifungals varied. The overall mortality rates were high (40.5%), with no significant difference in median survival between colonized and infected patients.

Conclusions: We reported a high rate of infection in previously colonized cases associated with longer hospital lenght stay, and a high susceptibility to echinocandins.

墨西哥爆发多中心念珠菌疫情:2020-2023 年。
白色念珠菌是一种新出现的耐多药酵母菌,由于其与医院内疫情爆发和抗真菌药物耐药性有关,已成为全球关注的问题。COVID-19 的大流行加剧了这一状况,据报道,包括墨西哥在内的世界各地已爆发了多起疫情。我们描述了墨西哥私立机构爆发的多中心疫情的临床和微生物学特征。我们在墨西哥蒙特雷的四家克里斯特斯-穆格萨医院医疗保健系统机构开展了一项回顾性观察研究,这些机构同时爆发了肠杆菌病。研究纳入了 2020 年 9 月至 2023 年 12 月期间定植或感染阴道杆菌的患者。分析显示,37 例病例主要为男性(年龄中位数为 55.8 岁)。虽然大多数病例最初都是定植,但相当一部分病例发展为感染(32.4%)。有感染记录的患者在重症监护室和医院的住院时间较长,通常需要机械通气。抗真菌治疗方法多种多样,大多数病例的首选药物是氟康唑,其次是阿尼芬净(anidulafungin)和卡泊芬净(caspofungin)。患者普遍对氟康唑产生抗药性,但对其他抗真菌药物的敏感性各不相同。总死亡率很高(40.5%),定植患者和感染患者的中位生存率没有明显差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.40
自引率
4.10%
发文量
479
审稿时长
24 days
期刊介绍: AJIC covers key topics and issues in infection control and epidemiology. Infection control professionals, including physicians, nurses, and epidemiologists, rely on AJIC for peer-reviewed articles covering clinical topics as well as original research. As the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC)
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信